Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

China’s Zhejiang Huahai Pharmaceutical has been named in U.S. litigation after its valsartan API was found to contain a suspected carcinogen.

It’s no secret that Takeda’s pending Shire megadeal has its critics, and some of them are now demanding behind-the-scenes info to justify the buy.

Nestlé, Unilever and Coca-Cola advanced to a second round of bidding for GSK's Indian consumer products business.

The EMA has taken action against China’s Zhejiang Huahai, whose valsartan API has been found to contain a suspected carcinogen.

Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.

U.S. medtech exports to China are targets in trade war; Alunbrig beats Xalkori in 1st-line lung cancer; FDA blasts Huahai for careless process changes.

China’s PharmaBlock Sciences says it has acquired a GMP-compliant manufacturing facility from Porton Pharma Solutions in Shangyu, China.